Curbing Drug Costs- Should Hungary Become A Role Model?

Published Oct 8, 2013
Ljubljana, Slovenia – Trying to control spending on prescription drugs is difficult because the many reasons for pharmaceutical expenditure growth are usually addressed only partially with national prescription drug policies. With the introduction of the Pharma Economic Act (PEA) in January 2007, Hungarian authorities took an approach that not only focused on the price of prescription drugs, but also introduced strong mechanisms to control the volume of drugs dispensed by the pharmaceutical companies. The recent economic crisis is making »laboratory of cost-containment tools«  attractive for authorities not only among the Central and Eastern European (CEE) countries, but also among Western (e.g., EU-15) jurisdictions. As with all austerity measures, there is always a risk that cost-containment acts may jeopardize innovation and could even lead to withdrawals of breakthrough branded drugs. The study has shown that Hungarian authorities managed to control the costs of prescription drugs and there is no reason to believe that the cost-containment policies were excluding innovation. Rok Hren, PhD, MSc IHP (HE), Professor, University of Ljubljana, says that, “Prior to the PEA, Hungarian authorities set up an excellent IT system for tracking the number of prescription drugs dispensed and associated public expenditure and co-payments; while most of jurisdictions in EU have in place electronic prescribing systems. The analysis provided to the public by the Hungarian authorities is exemplary in the CEE region and maybe even wider. Making data on prescription drug expenditures and associated co-payments publicly available is an item which should be definitely followed by the surrounding jurisdictions.” The full study, “Impact of the Pharma Economic Act on Diffusion of Innovation and Reduction of Costs in the Hungarian Prescription Drug Market (2007-2010),” is published in Value in Health Regional Issues.
Value in Health Regional Issues  (ISSN 2212-1099) is a scientific journal that encourages and enhances the science of pharmacoeconomic/health economic and health outcomes research and its use in health care decisions. The journal is published up to three times a year with one issue focusing on the Asia region, one issue focusing on the Latin America region, and one issue focusing on the Central & Eastern Europe, Western Asia and Africa regions. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

Related Stories

Value in Health Regional Issues Expands Editorial Scope and Reveals Plans to Transition to Gold Open Access Model

Jan 23, 2024

Value in Health Regional Issues, an official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the expansion of its editorial scope and its plan to transition to a gold open access journal.

Empowering Change: Transforming Health Systems in Low- and Middle-Income Countries

Jan 22, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health Regional Issues that highlight innovative approaches to improving health outcomes in low- and middle-income countries through partnerships between health economics researchers and policy makers.

ISPOR’s Value in Health Regional Issues Receives Its First Impact Factor Score

Aug 7, 2023

Value in Health Regional Issues, the regionally focused journal of ISPOR, received its first-ever impact factor score this year. Value in Health, one of the top-ranked journals in the HEOR field, maintained its high ranking on the prestigious list of scholarly journals.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now